Retains Crescendo Communications for Investor
Relations Services
Medexus Pharmaceuticals Inc. (formerly Pediapharm
Inc.) (the “Company” or “Medexus”) (TSXV: MDP, OTCQB:
PDDPF) today announced that it plans to host a conference
call at 4:30 PM Eastern Time on Monday, February 25, 2019 to
discuss the Company’s financial results for the fiscal third
quarter ended December 31, 2018, as well as the Company’s corporate
progress and other developments. The Company also announced it has
retained Crescendo Communications, LLC ("Crescendo”) to provide
investor relations services for the Company.
Ken d’Entremont, Chief Executive Officer of
Medexus, commented, “2018 was a transformative year for the
Company, as we consummated the merger between Pediapharm Inc.,
Medexus Inc. and Medac Pharma, Inc. We are making rapid
progress with the integration and look forward to working closely
with Crescendo to more proactively communicate the market
opportunity and commercial potential following this combination.
Accordingly, we look forward to hosting quarterly conference calls
with our investors going forward.”
“As a result of the recent mergers, Medexus now
operates through two segments, each with significant opportunities
and substantial synergies. In addition to a robust product
pipeline, we believe Medexus is well positioned in the market given
the organic revenue growth, positive EBITDA, scalable
infrastructure and solid balance sheet,” noted David Waldman, CEO
of Crescendo Communications. “We look forward to working closely
with Medexus to help increase awareness of the Company within the
U.S. investment community.”
Conference Call Details
The conference call will be available via
telephone by dialing toll free 866-682-6100 for Canadian and U.S.
callers or +1 862-298-0702 for international callers, or on the
Company’s Investor Events section of the website:
https://www.medexusinc.com/events/.
A webcast replay will be available on the
Company’s Investor Events section of the website
(https://www.medexusinc.com/events/) through May 25, 2019. A
telephone replay of the call will be available approximately one
hour following the call, through March 4, 2019, and can be accessed
by dialing 877-481-4010 for Canadian and U.S. callers or +1
919-882-2331 for international callers and entering conference ID:
43906.
The investor relations services agreement with
Crescendo (the “Agreement”) is for an indeterminate term and may be
terminated by Medexus at any time upon 30 days’ notice. Under the
terms of the Agreement, Crescendo will provide, among other things,
capital markets strategic advisory services and will assist the
Company with market intelligence and investor targeting and events.
Under the Agreement, Crescendo will receive a monthly fee of
US$10,000 and eligible expenses will be reimbursed. The Agreement
is subject to the approval of the TSX Venture Exchange.
About Medexus Pharmaceuticals
Inc.
Medexus Pharmaceuticals Inc. is a leading
specialty pharmaceutical company with a strong North American
commercial platform. The Company’s vision is to provide the best
healthcare products to healthcare professionals and patients,
through our core values of Quality, Innovation, Customer Service
and Teamwork. Medexus Pharmaceuticals is focused on the
therapeutic areas of auto-immune disease and pediatrics. The
leading products are Rasuvo and Metoject, a unique formulation of
methotrexate (auto-pen and pre-filled syringe) designed to treat
rheumatoid arthritis and other auto-immune diseases; and Rupall, an
innovative allergy medication with a unique mode of action.
For more information, please
contact:
Ken d’Entremont, Chief Executive OfficerMedexus
Pharmaceuticals Inc.Tel.: 905-676-0003E-mail:
ken.dentremont@medexus.ca
Roland Boivin, Chief Financial OfficerMedexus
Pharmaceuticals Inc.Tel.: 514-762-2626 ext. 202E-mail:
roland.boivin@medexusinc.com
Investor Relations (U.S.):Crescendo
Communications, LLCTel: +1-212-671-1020Email:
ACST@crescendo-ir.com
Investor Relations (Canada):Frank CandidoDirect
Financial Strategies and Communication Inc.Tel: 514-969-5530E-mail:
frank.candido@medexusinc.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
READER ADVISORIES
Forward Looking Statements This press release
contains “forward-looking information” within the meaning of
applicable securities legislation. Forward-looking information
includes, but is not limited to, statements with respect to future
business operation and results. All statements, other than of
historical fact, that address activities, events or developments
that the Company believes, expects or anticipates will or may occur
in the future are forward-looking statements. Forward-looking
statements are generally identifiable by use of the words “may”,
“will”, “should”, “continue”, “expect”, “anticipate”, “estimate”,
“believe”, “intend”, “plan” or “project” or the negative of these
words or other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the risk that the
operations of the Company, Medac Pharma and Medexus will not be
integrated successfully and the general risk that the Company's
anticipated revenue growth and EBITDA will not meet current levels
or future expectations, as well as other risks disclosed in the
Company's public disclosure record on file with the relevant
securities regulatory authorities. Although the Company believes
that the expectations and assumptions on which such forward-looking
information is based are reasonable, undue reliance should not be
placed on the forward-looking information because Company can give
no assurance that they will prove to be correct. Since
forward-looking information addresses future events and conditions,
by its very nature they involve inherent risks and uncertainties.
The Company’s actual results, performance or achievement could
differ materially from those expressed in, or implied by, the
forward-looking information and, accordingly, no assurance can be
given that any of the events anticipated by the forward-looking
information will transpire or occur, or if any of them do so, what
benefits that Company will derive therefrom. Management has
included the above summary of assumptions and risks related to
forward-looking information provided in this press release in order
to provide securityholders with a more complete perspective on the
Company's future operations and such information may not be
appropriate for other purposes. Readers should not place undue
reliance on forward-looking statements. Readers are cautioned that
the foregoing lists of factors are not exhaustive. Additional
information on these and other factors that could affect the
Company's operations or financial results are included in reports
on file with applicable securities regulatory authorities and may
be accessed through the SEDAR website (www.sedar.com). The
forward-looking statements included in this news release are made
as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or
otherwise unless required by applicable securities legislation.
NON-IFRS FINANCIAL MEASURES
The term EBITDA is used in this press release.
The term EBITDA (earnings before interest, taxes, depreciation and
amortization) does not have any standardized meaning under IFRS and
therefore may not be comparable to similar measures presented by
other companies. Rather, this measure is provided as additional
information to complement IFRS measures by providing a further
understanding of operations from management’s perspective.
See the Company's management discussion and analysis and other
reports on wile with applicable securities regulatory authorities
accessible through the SEDAR website (www.sedar.com) for a further
description of how the Company uses non-IFRS financial
measures.
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jul 2023 to Jul 2024